Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL.
Jonathan C AlsopJennie MedinChristian CornelissenStefan Viktor VormfeldeTjalf ZiemssenPublished in: PloS one (2017)
Fingolimod appears to be more effective than BRACE in improving clinical and physician-/patient-reported outcomes in individuals with active MS.